Similar effectiveness of dapagliflozin and GLP‐1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study

AIMS: According to cardiovascular outcome trials, some sodium‐glucose contransporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2D). In this real‐world study, we compared the simultaneous...

Descripción completa

Detalles Bibliográficos
Autores principales: Fadini, Gian Paolo, Sciannameo, Veronica, Franzetti, Ivano, Bottigliengo, Daniele, D'Angelo, Paola, Vinci, Carmela, Berchialla, Paola, Arena, Salvatore, Buzzetti, Raffaella, Avogaro, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767088/
https://www.ncbi.nlm.nih.gov/pubmed/30985052
http://dx.doi.org/10.1111/dom.13747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767088/
https://www.ncbi.nlm.nih.gov/pubmed/30985052
http://dx.doi.org/10.1111/dom.13747

Ejemplares similares